Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

The evolution of breast cancer diagnosis and treatment is an epic journey spanning past and present, marked by breakthroughs that have profoundly changed patient outcomes. From January 9 to 11, 2026, the Northern China Breast Cancer Salon · Annual Progress Review was held in Beijing. One of the most anticipated sessions was the Annual Review of Advances in Breast Cancer Therapy, which brought together leading experts to focus on the most significant international and domestic developments of 2025. Topics ranged from surgery, pathology, and radiotherapy to molecular classification and subtype-specific treatment, with in-depth discussion and synthesis of research that has reshaped clinical practice.
Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

The evolution of breast cancer diagnosis and treatment is an epic journey spanning past and present, marked by transformative breakthroughs that have profoundly reshaped patient outcomes. From January 9 to 11, 2026, the Northern China Breast Cancer Salon · Annual Progress Review was held in Beijing. One of the most highly anticipated sessions was the Annual Review of Advances in Breast Cancer Therapy, which brought together leading experts to examine and synthesize the most significant international and domestic developments of 2025. Topics ranged from surgery, pathology, and radiotherapy to molecular classification and precision treatment, highlighting studies that have reshaped clinical practice.
Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

From January 16 to 18, 2026, the Working Meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Myeloma Expert Committee and the 2026 CSCO Academic Conference on Hematologic Malignancies were held in Haikou, China. During the meeting, Professor Honghu Zhu of Beijing Chaoyang Hospital, Capital Medical University, provided a comprehensive overview of the current challenges of hematopoietic stem cell transplantation (HSCT) in acute leukemia, the evolution of transplant indications in the era of novel agents, and future optimization strategies. His insights offered important guidance for clinicians seeking to refine treatment approaches.
CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

With continuous technological iteration in CAR-T cell therapy, fourth-generation CAR-T is increasingly demonstrating substantial clinical potential. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The meeting brought together leading hematology experts from China and abroad, focusing on cutting-edge advances and national health strategy priorities, fostering in-depth academic exchange and exploration of new directions in the field.
Annual Review Professor Bing Xu: Interpreting New Paradigms and Future Pathways in the Diagnosis and Treatment of Follicular Lymphoma

Annual Review Professor Bing Xu: Interpreting New Paradigms and Future Pathways in the Diagnosis and Treatment of Follicular Lymphoma

From January 16 to 18, 2026, the Working Meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Myeloma Expert Committee and the 2026 CSCO Academic Conference on Hematologic Malignancies were held in Haikou, China. During the meeting, Professor Bing Xu of the First Affiliated Hospital of Xiamen University systematically outlined a comprehensive new framework for follicular lymphoma (FL), spanning precision risk stratification, therapeutic decision-making, and future research directions. His presentation provided valuable guidance for clinicians seeking to optimize treatment strategies and anticipate future developments in the field.
CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome that poses significant clinical challenges due to marked patient heterogeneity, a high proportion of relapsed or refractory cases, and limited options for precision-based interventions. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The conference brought together leading hematology experts from China and abroad, focusing on cutting-edge scientific advances and national health strategy priorities, fostering in-depth academic exchange and exploration of future directions in the field.
CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

The “Tianjin Model” of hematopoietic stem cell transplantation (HSCT) is a distinctive transplant system that integrates standardization, precision, and innovation. It has been progressively developed through nearly four decades of continuous exploration and generational knowledge transfer at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (also known as the Tianjin Institute of Hematology).
Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) was recently successfully held in Orlando, United States. As the year’s flagship event in hematology, the meeting presented a concentrated series of groundbreaking advances in lymphoma research, offering new directions for the optimization of clinical practice.
Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

At the beginning of 2026, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was grandly held in Beijing. The meeting focused on frontier advances and standardized practices in urologic oncology and brought together numerous domestic experts and scholars in the field.